Comparative studies of drotaverine-acephyllinate (Depogen) and pentoxifylline (Trental)
Pentoxifylline is an orally active agent for the treatment of peripherial and cerebral vascular diseases. Pentoxifylline increases the deformability of red blood cells in vitro, reduces blood viscosity and decreases platelet aggregation and thrombus formation. Depogen has shown antiaggregatory effec...
Gespeichert in:
| Veröffentlicht in: | Thrombosis research 1992-06, Vol.66 (6), p.693-706 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 706 |
|---|---|
| container_issue | 6 |
| container_start_page | 693 |
| container_title | Thrombosis research |
| container_volume | 66 |
| creator | Kapui, Z. Hermecz, I. Sarkadi, B. Szentmiklósi, P. Tardos, L. Blaskó, Gy |
| description | Pentoxifylline is an orally active agent for the treatment of peripherial and cerebral vascular diseases. Pentoxifylline increases the deformability of red blood cells in vitro, reduces blood viscosity and decreases platelet aggregation and thrombus formation. Depogen has shown antiaggregatory effect both in vitro and in ex vivo. The inhibitory effect of Pentoxifylline was about 3–5 times weaker than that of Depogen. IC
50=900/ug/ml for Depogen and 3600/ug/ml for Pentoxifylline on human platelet rich plasma. Depogen has shown ex vivo antiaggregatory effect on anaesthetised rabbits, ID
50=7 mg/kg in case of iv. administration, and ID
50=300 mg/kg in case of orally administration. Both compound inhibit the release of platelet precoagulation factor, but the effect of Pentoxifylline was slighter. |
| doi_str_mv | 10.1016/0049-3848(92)90045-C |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_73176334</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>004938489290045C</els_id><sourcerecordid>73176334</sourcerecordid><originalsourceid>FETCH-LOGICAL-c386t-b2da36199f9360725b191768cf666e68ca0b3d85e310f935e429f803d28269683</originalsourceid><addsrcrecordid>eNp9kMtKxDAUhoMoOl7eQKELEWdRzaVNk40g9QoDbkZchkxyqpFOU5POoG9vxhl05-qQ_N_5Ez6Ejgm-IJjwS4wLmTNRiHNJxzKdyrzeQiMiKpnToqLbaPSL7KH9GN8xJhWR5S7aJSWRlIoReqn9vNdBD24JWRwW1kHMfJPZ4Ae9hOA6yLWB_u2rbV2nB8jOb6D3r9CNM93ZrIdu8J-u-YlTOA3pQrfjQ7TT6DbC0WYeoOe722n9kE-e7h_r60lumOBDPqNWM06kbCTjuKLljEhScWEazjmkqfGMWVECIzghJRRUNgIzSwXlkgt2gM7WvX3wHwuIg5q7aKBtdQd-EVXFUh1jRQKLNWiCjzFAo_rg5jp8KYLVyqdayVIrWUpS9eNT1WntZNO_mM3B_i2tBab8dJPraHTbBN0ZF3-xgqX3S5qwqzUGycXSQVDROOgMWBfADMp69_8_vgFShpCG</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>73176334</pqid></control><display><type>article</type><title>Comparative studies of drotaverine-acephyllinate (Depogen) and pentoxifylline (Trental)</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><creator>Kapui, Z. ; Hermecz, I. ; Sarkadi, B. ; Szentmiklósi, P. ; Tardos, L. ; Blaskó, Gy</creator><creatorcontrib>Kapui, Z. ; Hermecz, I. ; Sarkadi, B. ; Szentmiklósi, P. ; Tardos, L. ; Blaskó, Gy</creatorcontrib><description>Pentoxifylline is an orally active agent for the treatment of peripherial and cerebral vascular diseases. Pentoxifylline increases the deformability of red blood cells in vitro, reduces blood viscosity and decreases platelet aggregation and thrombus formation. Depogen has shown antiaggregatory effect both in vitro and in ex vivo. The inhibitory effect of Pentoxifylline was about 3–5 times weaker than that of Depogen. IC
50=900/ug/ml for Depogen and 3600/ug/ml for Pentoxifylline on human platelet rich plasma. Depogen has shown ex vivo antiaggregatory effect on anaesthetised rabbits, ID
50=7 mg/kg in case of iv. administration, and ID
50=300 mg/kg in case of orally administration. Both compound inhibit the release of platelet precoagulation factor, but the effect of Pentoxifylline was slighter.</description><identifier>ISSN: 0049-3848</identifier><identifier>EISSN: 1879-2472</identifier><identifier>DOI: 10.1016/0049-3848(92)90045-C</identifier><identifier>PMID: 1519228</identifier><identifier>CODEN: THBRAA</identifier><language>eng</language><publisher>New York, NY: Elsevier Ltd</publisher><subject>acephyllinate ; Animals ; Biological and medical sciences ; Cardiovascular system ; Cell Aggregation - drug effects ; Depogen ; Drug Combinations ; Drug Evaluation, Preclinical ; Erythrocytes - drug effects ; Humans ; Leukocytes - drug effects ; Medical sciences ; Papaverine - analogs & derivatives ; Papaverine - pharmacology ; Pentoxifylline - pharmacology ; Pentoxifylline, Drotaverine ; Pharmacology. Drug treatments ; Platelet Aggregation - drug effects ; Platelet Aggregation Inhibitors - pharmacology ; platelet aggregation, Trental ; Platelet Factor 3 - antagonists & inhibitors ; Rabbits ; Theophylline - analogs & derivatives ; Theophylline - pharmacology ; Vasodilator agents. Cerebral vasodilators</subject><ispartof>Thrombosis research, 1992-06, Vol.66 (6), p.693-706</ispartof><rights>1992</rights><rights>1993 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c386t-b2da36199f9360725b191768cf666e68ca0b3d85e310f935e429f803d28269683</citedby><cites>FETCH-LOGICAL-c386t-b2da36199f9360725b191768cf666e68ca0b3d85e310f935e429f803d28269683</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/0049-3848(92)90045-C$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=4331752$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/1519228$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kapui, Z.</creatorcontrib><creatorcontrib>Hermecz, I.</creatorcontrib><creatorcontrib>Sarkadi, B.</creatorcontrib><creatorcontrib>Szentmiklósi, P.</creatorcontrib><creatorcontrib>Tardos, L.</creatorcontrib><creatorcontrib>Blaskó, Gy</creatorcontrib><title>Comparative studies of drotaverine-acephyllinate (Depogen) and pentoxifylline (Trental)</title><title>Thrombosis research</title><addtitle>Thromb Res</addtitle><description>Pentoxifylline is an orally active agent for the treatment of peripherial and cerebral vascular diseases. Pentoxifylline increases the deformability of red blood cells in vitro, reduces blood viscosity and decreases platelet aggregation and thrombus formation. Depogen has shown antiaggregatory effect both in vitro and in ex vivo. The inhibitory effect of Pentoxifylline was about 3–5 times weaker than that of Depogen. IC
50=900/ug/ml for Depogen and 3600/ug/ml for Pentoxifylline on human platelet rich plasma. Depogen has shown ex vivo antiaggregatory effect on anaesthetised rabbits, ID
50=7 mg/kg in case of iv. administration, and ID
50=300 mg/kg in case of orally administration. Both compound inhibit the release of platelet precoagulation factor, but the effect of Pentoxifylline was slighter.</description><subject>acephyllinate</subject><subject>Animals</subject><subject>Biological and medical sciences</subject><subject>Cardiovascular system</subject><subject>Cell Aggregation - drug effects</subject><subject>Depogen</subject><subject>Drug Combinations</subject><subject>Drug Evaluation, Preclinical</subject><subject>Erythrocytes - drug effects</subject><subject>Humans</subject><subject>Leukocytes - drug effects</subject><subject>Medical sciences</subject><subject>Papaverine - analogs & derivatives</subject><subject>Papaverine - pharmacology</subject><subject>Pentoxifylline - pharmacology</subject><subject>Pentoxifylline, Drotaverine</subject><subject>Pharmacology. Drug treatments</subject><subject>Platelet Aggregation - drug effects</subject><subject>Platelet Aggregation Inhibitors - pharmacology</subject><subject>platelet aggregation, Trental</subject><subject>Platelet Factor 3 - antagonists & inhibitors</subject><subject>Rabbits</subject><subject>Theophylline - analogs & derivatives</subject><subject>Theophylline - pharmacology</subject><subject>Vasodilator agents. Cerebral vasodilators</subject><issn>0049-3848</issn><issn>1879-2472</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1992</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kMtKxDAUhoMoOl7eQKELEWdRzaVNk40g9QoDbkZchkxyqpFOU5POoG9vxhl05-qQ_N_5Ez6Ejgm-IJjwS4wLmTNRiHNJxzKdyrzeQiMiKpnToqLbaPSL7KH9GN8xJhWR5S7aJSWRlIoReqn9vNdBD24JWRwW1kHMfJPZ4Ae9hOA6yLWB_u2rbV2nB8jOb6D3r9CNM93ZrIdu8J-u-YlTOA3pQrfjQ7TT6DbC0WYeoOe722n9kE-e7h_r60lumOBDPqNWM06kbCTjuKLljEhScWEazjmkqfGMWVECIzghJRRUNgIzSwXlkgt2gM7WvX3wHwuIg5q7aKBtdQd-EVXFUh1jRQKLNWiCjzFAo_rg5jp8KYLVyqdayVIrWUpS9eNT1WntZNO_mM3B_i2tBab8dJPraHTbBN0ZF3-xgqX3S5qwqzUGycXSQVDROOgMWBfADMp69_8_vgFShpCG</recordid><startdate>19920615</startdate><enddate>19920615</enddate><creator>Kapui, Z.</creator><creator>Hermecz, I.</creator><creator>Sarkadi, B.</creator><creator>Szentmiklósi, P.</creator><creator>Tardos, L.</creator><creator>Blaskó, Gy</creator><general>Elsevier Ltd</general><general>Elsevier Science</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>19920615</creationdate><title>Comparative studies of drotaverine-acephyllinate (Depogen) and pentoxifylline (Trental)</title><author>Kapui, Z. ; Hermecz, I. ; Sarkadi, B. ; Szentmiklósi, P. ; Tardos, L. ; Blaskó, Gy</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c386t-b2da36199f9360725b191768cf666e68ca0b3d85e310f935e429f803d28269683</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1992</creationdate><topic>acephyllinate</topic><topic>Animals</topic><topic>Biological and medical sciences</topic><topic>Cardiovascular system</topic><topic>Cell Aggregation - drug effects</topic><topic>Depogen</topic><topic>Drug Combinations</topic><topic>Drug Evaluation, Preclinical</topic><topic>Erythrocytes - drug effects</topic><topic>Humans</topic><topic>Leukocytes - drug effects</topic><topic>Medical sciences</topic><topic>Papaverine - analogs & derivatives</topic><topic>Papaverine - pharmacology</topic><topic>Pentoxifylline - pharmacology</topic><topic>Pentoxifylline, Drotaverine</topic><topic>Pharmacology. Drug treatments</topic><topic>Platelet Aggregation - drug effects</topic><topic>Platelet Aggregation Inhibitors - pharmacology</topic><topic>platelet aggregation, Trental</topic><topic>Platelet Factor 3 - antagonists & inhibitors</topic><topic>Rabbits</topic><topic>Theophylline - analogs & derivatives</topic><topic>Theophylline - pharmacology</topic><topic>Vasodilator agents. Cerebral vasodilators</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kapui, Z.</creatorcontrib><creatorcontrib>Hermecz, I.</creatorcontrib><creatorcontrib>Sarkadi, B.</creatorcontrib><creatorcontrib>Szentmiklósi, P.</creatorcontrib><creatorcontrib>Tardos, L.</creatorcontrib><creatorcontrib>Blaskó, Gy</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Thrombosis research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kapui, Z.</au><au>Hermecz, I.</au><au>Sarkadi, B.</au><au>Szentmiklósi, P.</au><au>Tardos, L.</au><au>Blaskó, Gy</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Comparative studies of drotaverine-acephyllinate (Depogen) and pentoxifylline (Trental)</atitle><jtitle>Thrombosis research</jtitle><addtitle>Thromb Res</addtitle><date>1992-06-15</date><risdate>1992</risdate><volume>66</volume><issue>6</issue><spage>693</spage><epage>706</epage><pages>693-706</pages><issn>0049-3848</issn><eissn>1879-2472</eissn><coden>THBRAA</coden><abstract>Pentoxifylline is an orally active agent for the treatment of peripherial and cerebral vascular diseases. Pentoxifylline increases the deformability of red blood cells in vitro, reduces blood viscosity and decreases platelet aggregation and thrombus formation. Depogen has shown antiaggregatory effect both in vitro and in ex vivo. The inhibitory effect of Pentoxifylline was about 3–5 times weaker than that of Depogen. IC
50=900/ug/ml for Depogen and 3600/ug/ml for Pentoxifylline on human platelet rich plasma. Depogen has shown ex vivo antiaggregatory effect on anaesthetised rabbits, ID
50=7 mg/kg in case of iv. administration, and ID
50=300 mg/kg in case of orally administration. Both compound inhibit the release of platelet precoagulation factor, but the effect of Pentoxifylline was slighter.</abstract><cop>New York, NY</cop><pub>Elsevier Ltd</pub><pmid>1519228</pmid><doi>10.1016/0049-3848(92)90045-C</doi><tpages>14</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0049-3848 |
| ispartof | Thrombosis research, 1992-06, Vol.66 (6), p.693-706 |
| issn | 0049-3848 1879-2472 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_73176334 |
| source | MEDLINE; Elsevier ScienceDirect Journals Complete |
| subjects | acephyllinate Animals Biological and medical sciences Cardiovascular system Cell Aggregation - drug effects Depogen Drug Combinations Drug Evaluation, Preclinical Erythrocytes - drug effects Humans Leukocytes - drug effects Medical sciences Papaverine - analogs & derivatives Papaverine - pharmacology Pentoxifylline - pharmacology Pentoxifylline, Drotaverine Pharmacology. Drug treatments Platelet Aggregation - drug effects Platelet Aggregation Inhibitors - pharmacology platelet aggregation, Trental Platelet Factor 3 - antagonists & inhibitors Rabbits Theophylline - analogs & derivatives Theophylline - pharmacology Vasodilator agents. Cerebral vasodilators |
| title | Comparative studies of drotaverine-acephyllinate (Depogen) and pentoxifylline (Trental) |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-03T09%3A39%3A09IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Comparative%20studies%20of%20drotaverine-acephyllinate%20(Depogen)%20and%20pentoxifylline%20(Trental)&rft.jtitle=Thrombosis%20research&rft.au=Kapui,%20Z.&rft.date=1992-06-15&rft.volume=66&rft.issue=6&rft.spage=693&rft.epage=706&rft.pages=693-706&rft.issn=0049-3848&rft.eissn=1879-2472&rft.coden=THBRAA&rft_id=info:doi/10.1016/0049-3848(92)90045-C&rft_dat=%3Cproquest_cross%3E73176334%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=73176334&rft_id=info:pmid/1519228&rft_els_id=004938489290045C&rfr_iscdi=true |